CD19 and hematopoietic and lymphoid cell neoplasm: We provide compelling in vitro evidence that redirecting anti-CMV T immunity by CD19-ReTARGTPR potently eliminates CD19pos hematological cancer cells, without inducing supraphysiological cytokine responses, as seen during the CAR T cell and BiTE treatments used clinically.